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Abstract
Background—A genetic contribution to smoking behavior is well established. To identify loci that
increase the risk for smoking behavior, many genomewide linkage scans have been performed using
various smoking behavior assessments. Numerous putative susceptibility loci have been identified,
but only a few of these were replicated in independent studies.
Methods—We used genome seach meta-analysis (GSMA) to identify risk loci by pooling all
available independent genome scan results on smoking behavior. Additionally, to minimize locus
heterogeneity, subgroup analyses of the smoking behavior assessed by the Fagerstrom test for
nicotine dependence (FTND) and maximum number of cigarettes smoked in a 24-hour period
(MaxCigs24) were carried out. Samples of European ancestry were also analyzed separately.
Results—A total number of 15 genome scan results were available for analysis, including 3404
families with 10,253 subjects. Overall, the primary GSMA across all smoking behavior identified a
genomewide suggestive linkage in chromosome 17q24.3–q25.3 (PSR=0.001). A secondary analysis
of FTND in European-ancestry samples (625 families with 1878 subjects) detected a genomewide
suggestive linkage in 5q33.1–5q35.2(PSR=0.0076).Subgroup analysis of MaxCigs24 (966 families
with 3273 subjects) identified a genomewide significant linkage in 20q13.12–q13.32 (PSR=0.00041,
POR=0.048), where a strongly supported ND candidate gene, CHRNA4, is located.
Conclusions—The regions identified in the current study deserve close attention and will be
helpful for candidate gene identification or target resequencing studies in the future.
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tIntroduction
Cigarette smoking is highly prevalent throughout many populations around the globe. Despite
increasing awareness of the risks associated with smoking, the World Health Organization
(1999) estimated that 1.1 billion people still smoke, and predicted that by 2025, the number
will increase to 1.6 billion worldwide. Thus, understanding various factors that influence
smoking behavior is critical to the prevention and cessation of smoking. Although the etiology
of smoking behavior is complex, a genetic contribution to smoking behavior, presumably based
on addiction to nicotine, is well established from twin and adoption studies (1,2). Genetic
linkage analysis can be a useful design to detect genes that segregate in families, including
common variants, multiple rare variants within one locus, and copy number variation.
More than 20 genomewide linkage scans on smoking behavior have been performed using a
variety of smoking behavior assessments, including DSM-IV defined nicotine dependence, the
Fagerstrom Test for Nicotine Dependence (FTND) (3,4), the Fagerstrom Tolerance
Questionnaire (FTQ), Fagerstrom-derived smoking quantity (SQ) and Heaviness of Smoking
Index (HSI), habitual smoking, persistent smoking, maximum number of cigarettes smoked in
a 24-hour period (MaxCigs24), and others (5–24). Numerous putative susceptibility loci have
been identified, but only a few of these have been replicated in independent studies, which is
not uncommon for linkage analysis of genetically complex traits. Considering the high
likelihood of many risk loci of low-to-moderate effect for complex traits and the relatively
small sample size in each study, the discrepancy among study results is expected, because a
single study may be statistically underpowered to detect a low magnitude but real genetic
linkage. Although literature reviews have provided valuable overviews of progress in linkage
studies on smoking behavior, they are not intended to provide formal statistical assessment of
pooled evidence for linkage across studies. Considering the quantity of accumulated genome
scan results on smoking behavior now available, a rigorous statistical method of synthesis of
the reported results for linkage could provide a powerful approach to detect previously
unappreciated linkage signals.
The genome search meta-analysis (GSMA) method has been proposed as a valid and robust
meta-analysis technique to combine the evidence for linkage across multiple linkage scans
using a non-parametric ranking method (25,26). Apart from the advantage of greater power in
detecting small but consistent evidence for linkage, GSMA can combine linkage results from
studies with different family structures, marker sets, and statistical analysis methods. While a
unique genetic spectrum might characterize each specific smoking behavior, we hypothesize
that some risk loci are shared across different assessments. Consequently, the aim of the current
study is to identify potential risk loci which are independent of distinct smoking behavior
assessments using the GSMA by pooling all independent genome scan results of smoking
behavior. Because increased sample homogeneity can be helpful to reduce locus heterogeneity
and therefore increase power to detect regions specific for a particularly defined sample set,
subgroup GSMA based on FTND and MaxCigs24 was carried out. Samples incorporating
subjects of mostly European ancestry were also analyzed separately.
Materials and Methods
Study samples
To identify existing genomewide linkage studies on smoking behavior, we conducted a
computerized literature search of the PubMed database using the following keywords and
subject terms: ‘linkage’, ‘smoking’, ‘nicotine dependence’, ‘genome-wide’, or ‘genomewide’.
Review articles on genetics of smoking behavior were also screened. The genome scans
included in the current GSMA were required to meet the following criteria: 1) whole genome
linkage scan on smoking related traits performed in humans; 2) whole genome linkage results
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teither available from the original investigators, or extractable from published graphs; 3)
samples used in genome scans should be independent of each other. Linkage studies which
were repeated analyses of the same sample using different statistical methods or phenotype
measures were identified, and we included only one independent study for which the whole
genome linkage results were available. In addition, when a study reported whole genome
linkage results on different samples; we treated each sample as a separate genome scan. When
a study reported a two-stage analysis, only the original results were used and any follow up
studies in candidate regions were excluded, as the GSMA requires a uniform distribution of
markers across the genome (25).
In total, 20 studies (24 genome scans, 5428 families) were identified (5–24), and finally 12
studies (15 complete genome scans, 3404 families) met criteria and were included in the GSMA
(5–16), as listed in Table 1. Eight studies (9 genome scans, 2024 families) were not included
for the following reasons (17–24). Four studies are repeated analyses of the Framingham Heart
Study (6,19–21); from these, the result from Goode (6) was used because the whole-genome
linkage result was available from the published graph. Three linkage analyses have been
performed on the data of the Collaborative Study on the Genetics of Alcoholism (7,17–18);
we used the result from Bierut (7) since the whole-genome linkage results were available from
the authors. Two linkage analyses on two different assessments of smoking behavior (9,22)
were performed for the same sample from the Netherlands Twin Register; the result for
“maximum number of cigarettes per day” was included (9). In the earliest study, the authors
carried out a 2-stage genome scan, and only the result from stage 1 was used since stage 2 was
a follow up genome scan in candidate regions (5). Finally, results for two studies (three genome
scans) were not available (23,24). In addition, two studies (15,16) used the same sample of
Finnish twin families, but performed the genome scan on different assessments of smoking
behavior (FTND and MaxCigs24). The result from Loukola (16) was included for the primary
GSMA on smoking behavior and FTND. The result from Saccone (15) was only used for the
secondary GSMA on MaxCigs24. Consequently, the data for this analysis were collected from
12 studies (15 genome scans), including 3404 families with 10,253 individuals.
Data extraction
The relevant characteristics of each study included in the GSMA are summarized in Table 1.
For each study, the following information was extracted: first author, journal, year of
publication, ethnicity of study population, number of families, subjects, definition of
phenotype, number of markers, linkage statistic, and software used for linkage analysis. If the
genomewide linkage results were available from the published graphs, the required linkage
statistics for GSMA were extracted from the figures by the digital software g3data
(http://www.frantz.fi/software/g3data.php). Otherwise, the authors were invited to contribute
the whole genome linkage results including marker names, genetic position and linkage
statistics for each marker. The authors of five studies including seven genome scans (7,13–
16) provided the original linkage results. Genetic map positions and marker locations were
unified based on the Marshfield genetic map.
Statistical analysis
The GSMA method was used to synthesize the evidence for linkage across multiple genome
scans. In the primary GSMA, chromosomes are divided into approximately equal length bins
traditionally ∼30 cM, generating a total number of 118 bins on the autosomes based on the
Marshfield genetic map. The notation “c.n” for the bin numbering is used to refer to the nth
bin on chromosome c. For each study, each bin was assigned a within-study rank by its highest
LOD, NPL or Z score or minimum P-value, so that the bin with the highest linkage score or
minimum P-value is assigned a rank 118 and other bins are ranked in the descending order of
their strength for linkage. The ranks were then summed across studies for each bin to obtain
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tthe summed rank (SR), which forms the basic test statistic for assessing linkage within the bin.
Bins with high SR may show significant evidence for linkage.
We used GSMA software (27) to evaluate empirically the significance of the SR. Briefly, for
each study, the observed rank values were randomly reassigned to 118 bins, allowing for tied
ranks in each study to be incorporated in the null distribution. Bin ranks were summed across
studies; this procedure was repeated 10,000 times. The empirical P-value of SR was calculated
by counting the proportion of bins in which a summed rank value was equal to or larger than
the observed one. In addition, a POR is calculated as the proportion of the simulated nth highest
ordered sum rank (OR), which is equal to or greater than the observed nth highest summed rank
through the same permutation procedure. Simulation studies have shown that bins with
significant P-values (P < 0.05) of both SR and OR are likely to identify true linkage signals
(26). By applying a Bonferroni correction for multiple testing (assuming 118 independent bins),
values of PSR, 0.05/118=0.00042 and 1/118=0.0085 correspond to the genomewide significant
and suggestive evidence for linkage, respectively. Simulation studies have shown that these
thresholds are appropriate for the GSMA (28), with a P-value exceeding the genomewide
significant threshold expected once by chance in 20 meta-analyses and a P-value exceeding
the genomewide suggestive threshold expected once by chance per single meta-analysis.
We performed both unweighted and weighted GSMA analysis. In unweighted analysis, each
study was assumed to contribute equally to the GSMA. The weighted GSMA takes into account
the relative contribution from each study. The most appropriate weighting factor is not obvious;
simulation studies have shown that the square root of the number of affected cases within each
study performed well (26). Since most of the phenotypes we included in this GSMA were
quantitative traits (FTND, MaxCigs24) and not binary outcomes, we used the square root of
the number of genotyped subjects in each study as the primary weighting factor and the relevant
results were reported in detail. To evaluate the influence of different weighting factors on the
results, we also used an alternative weighting factor defined by the square root of number of
pedigrees x number of markers used in each study (although we note that the latter is an
imperfect approximation of information content in each study owing to varying information
content from different markers, and diminishing information beyond a marker set that achieves
genomewide coverage).
A bin width of around 30 cM is used in the GSMA most frequently, and was demonstrated to
be optimal by simulation (26). In order to detect weak linkage signals near the boundary of
two bins, a shifted 30cM bin GSMA was also applied by moving bin boundaries 15 cM and
starting at the midpoint of the bins used in the primary 30 cM analysis (29).
Two major sources of heterogeneity in linkage studies arise from differing definitions of
smoking behavior and ethnicities of samples, since a variety of smoking behavior assessments
were included in the current GSMA across different populations. Although we postulated that
some genes that regulate smoking behavior might be independent of specific smoking behavior
assessments and population groups, restricting the combined analyses to studies with similar
ascertainment criteria or to subjects from similar ethnic backgrounds could potentially increase
power to detect linkage to particular regions where the relevant risk loci are specific either to
a trait or to a population. Therefore, subgroup analyses of the families assessed by FTND or
MaxCigs24 were performed. Subjects of European ancestry were also analyzed separately.
Other populations or phenotype groups had too few studies available for separate analysis.
Results
First, we performed the primary 30 cM bin width GSMA over all independent genome scans
on smoking behavior, encompassing 3404 families with 10,253 genotyped subjects. Figure 1
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tillustrates the weighted and unweighted PSR for all bins across the genome. The full details of
genetic regions showing bins with nominal significance in weighted analysis are shown in
Table 2, and the unweighted analysis results are also included as a comparison with weighted
analysis. The strongest evidence for a smoking behavior risk locus was found on chromosome
17q24.3–q25.3 (bin 17.4) where suggestive evidence for linkage was achieved by either
unweighted (PSR = 0.002) or weighted analysis (PSR = 0.001).
To identify loci that might increase susceptibility to a specific smoking behavior trait, we
performed subgroup GSMA over the genome scan results on the smoking behaviors measured
by FTND and MaxCigs24. Five genome scan results were included in the analysis of FTND
(1347 families with 3995 subjects). The weighted and unweighted PSR for all bins across the
genome are illustrated in Figure 2. There were no regions that achieved genomewide significant
or suggestive evidence for linkage, except six regions showed nominally significant evidence
for linkage in the weighted analysis (Table 3). In the subgroup analysis of MaxCigs24, four
genome scan results, all from European ancestry populations, were included (966 families with
3273 subjects). The genomewide results with weighted and unweighted analysis are illustrated
in Figure 3. A genomewide significant linkage was identified in 20q13.12–q13.32 by both
weighted (PSR=0.00041, POR=0.048) and unweighted analysis (PSR=0.00032, POR=0.037).
Three regions (22q12.3–q13.32, 20p12.1–q13.12 and 17q24.3–q25.3) achieved genomewide
suggestive evidence for linkage. Eleven regions on six chromosomes (2,12,16,17,20 and 22)
with both PSR and POR less than 0.05 are somewhat likely to harbor risk loci for MaxCigs24
trait (Table 4).
To increase homogeneity and evaluate population specific linkages, samples of European
ancestry (or mostly European ancestry) were analyzed separately. Since the primary GSMA
on MaxCigs24 only included European ancestry populations, secondary analysis by European
ancestry only needed to be carried out for smoking behavior and FTND. Figures S1 and S2 in
the Supplement illustrate the results across all bins for smoking behavior and FTND,
respectively. Here, we report the results of the European ancestry GSMA compared with the
overall GSMA in weighted analysis. Briefly, 11 genome scan results were included for analysis
of smoking behavior (2486 families with 7270 subjects). Bin 17.4 still achieved suggestive
linkage (PSR=0.002). Three bins (11.1, 3.8 and 5.4) were no longer significant and two bins
(22.2 and 5.6) became nominally significant (Table 2). For the FTND phenotype, three genome
scan results were included (625 families with 1878 subjects). Two bins (6.6 and 5.4) were no
longer significant and 2 bins (5.7 and 5.6) became significant (Table 3).
In order to identify weak linkage signals near the boundaries of two bins, we re-analyzed the
data using a shifted 30cM bin GSMA starting at the midpoint of the bins used in the primary
analysis. Figures S3, S4 and S5 in the Supplement illustrate the genomewide results using the
shifted 30cM GSMA for smoking behavior, FTND and MaxCigs24, respectively. Here, we
report the bins which achieved genomewide suggestive evidence for linkage (weighted
analysis) in this secondary analysis. In the analysis of smoking behavior, bin 16.1 (16p13.2–
16p12.1), achieved genomewide suggestive linkage in both all (PSR =0.0074) and European-
ancestry (PSR=0.0085) samples. Bin 5.6 (5q33.1–5q35.2) reached genomewide suggestive
linkage for FTND in European-ancestry samples (PSR=0.0076). In the analysis of the
MaxCigs24 trait, bin 22.1 (22q11.22–22q13.2) reached genomewide suggestive linkage
(PSR=0.0016).
Lastly, to evaluate how the different weighting factors could influence the results, we
performed the weighted analysis using the weighting factor defined by the square root of
number of pedigree x number of markers. As a result, we found that the resultant top ranked
bins and P-values, generated by the two weighting factors, remain close to each other.
Wilcoxon signed-rank test further showed no significant difference (P > 0.7) on the ranks of
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tbins by the two different weighting factors for each trait we investigated. A comparison of the
top five bins identified for each of the traits using both weighting approaches is shown in Table
S1 in the Supplement.
Discussion
The current GSMA, which included 3404 families with 10,253 subjects, has identified many
regions with varying degrees of evidence of linkage for smoking behavior. In the primary 30
cM GSMA of combined smoking behavior, genomewide suggestive linkage was detected at
chromosome 17q24.3–q25.3. The fact that we did not identify any bins with genomewide
significant evidence for linkage in the primary analysis might imply the possible relatively
higher genetic heterogeneity due to a variety of different smoking behaviors and sample
ancestry. Although only nominal significance was detected in the primary GSMA for the
FTND, genomewide suggestive linkage was observed in 5q33.1–5q35.2 by shifting the bin
boundary 15 cM in a secondary analysis of European-ancestry samples. Subgroup analysis of
the MaxCigs24 phenotype identified numerous linkage signals; this might be attributable to
the improved power from the increased homogeneity of both the phenotype and sample
ancestry. For example, a genomewide significant linkage in bin 20.3 (20q13.12–q13.32) was
identified, and the adjacent bin 20.2 (20p12.1–q13.12) showed suggestive linkage, providing
more support for a true linkage signal in this region. Eleven regions with both PSR and POR
<0.05 support that some or all of these 11 regions are likely to harbor risk loci for the
MaxCigs24 trait.
A necessary follow-up step is to evaluate if notable candidate genes map to regions nominated
by the current GSMA. A strong candidate gene for nicotine dependence, CHRNA4 (20q13.2–
q13.3) (30–34), is located in bin 20.3 (20q13.12–q13.32), where genomewide significant
linkage was reached in the primary GSMA of MaxCigs24. CHRNA4, which encodes the
nicotinic acetylcholine receptor α4 subunit gene, is highly expressed in the central nervous
system (CNS) and plays a major role in tolerance, reward, and the modulation of mesolimbic
dopamine function, all of which are critical to the development of nicotine dependence (35).
Two genes, PLEKHG1 (36) and OPRM1 (37), are located in bin 6.5 (6q23.2–q25.3), which
ranks highest and its adjacent bin 6.6 ranks second highest in the GSMA of FTND. The
PLEKHG1 gene contains a pleckstrin homology (PH) domain and is expressed in the brain
and peripheral nervous system (38). It is possible that variants of these PH-domain-containing
proteins have an impact on the cell-signaling pathways that regulate neuronal plasticity, and
thus could influence predisposition to ND. The µ-opioid receptor gene OPRM1 has been found
to be associated with FTQ nicotine dependence (37) and plays a role in substance use and
dependence across several drug classes (39–41). Two other previously identified candidate
genes, DRD4 (42,43) and COMT (44), are located at bin 11.1 and bin 22.1 respectively, each
of which showed nominal significance in the primary GSMA of smoking behavior or
MaxCigs24. Some other well known candidate genes, such as the NCAM1-TTC12-ANKK1-
DRD2 gene cluster (45,46) and DDC (47,48), are not represented in any of the chromosomal
regions identified. These findings might reflect the possibility that the effect size of these genes
is too small to be detected by the current GSMA.
Recent genomewide association studies (GWAS) have identified many more genes implicated
in smoking behavior. The first GWAS on smoking using sample pooling and 2.4 million SNPs
suggested several novel genes possibly associated with ND (49). Among the top candidate
genes list in this first GWAS, five genes were located in the GSMA nominated bins: NRXN1
in bin 2.3 (2p22.1-p13.2), FTO in bin 16.2 (16p12.3-q12.2), GPSM3 in bin 20.2 (20p12.1–
q13.12), TRPC7 in bin 5.6 (5q31.2–q34) and FBXL17 in bin 5.4 (5q14.1–q21.3). Another
recent GWAS on smoking behavior (50) was conducted for a sample of 840 European-ancestry
subjects using ∼380,000 SNPs, and has also identified genes possibly associated with smoking
Han et al. Page 6
Biol Psychiatry. Author manuscript; available in PMC 2011 January 1.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tbehavior, among which five genes map within regions discovered by the GSMA:
TBC1D22A in bin 22.2 (22q12.3–q13.32), PDE10A in bin 6.6 (6q25.3–q27), RDH11 in bin
14.3 (14q23.3–q31.1), CENTD3 in bin 5.6 (5q31.2–q34) and LEP in bin 7.5 (7q31.1–q34).
Several GWAS have consistently identified a region on chromosome 15q24 associated with
smoking intensity or lung cancer (51–55). Candidate gene studies have also confirmed the
association between variation mapped to the gene cluster (CHRNA5, CHRNA3 and
CHRNB4) at 15q24 and different smoking behaviors (34,56–59). We are not aware of any
individual genomewide linkage scan which has reported genomewide suggestive or significant
linkage in the region of 15q24. Our primary 30 cM width GSMA did not detect any signal in
15q24, but we did find PSR=0.058 at bin 15.2 (15q21.1–q25.1) which covered the region 15q24
in the 30 cM shifted GSMA of smoking behavior in the European descent populations. The
evidence for linkage obtained from the current GSMA thus fails to provide linkage support for
the region 15q24 that apparently harbors ND susceptibility genes. The fact that we did not find
any stronger evidence for linkage in this region might imply that the genetic effect is small and
the current GSMA does not have sufficient power to achieve significant evidence for linkage
in this region or that the heterogeneity among different samples obscure the discovery of some
linkage loci with minor effects. This is hard to reconcile with the consistency with which this
region has been identified in the GWAS.
We discuss briefly additional novel candidate genes mapped to regions discovered by the
GSMA. In particular, we focus on the region of chromosome 17q24.3–q25.3 (bin 17.4), since
this region ranks highest in the meta-analysis of the combined smoking behavior, and was
consistently nominated by the meta-analysis of FTND and MaxCigs24. According to NCBI
database information (http://www.ncbi.nlm.nih.gov/), there are 253 genes in 17q24.3–q25.3,
among which we find two particularly promising candidate genes for smoking. One gene is G
protein pathway suppressor 1 (GPS1), which suppresses G-protein and mitogen-activated
signal transduction. Variants of this gene might influence the regulation of the dopamine
signaling pathway and associated with smoking behavior. Another promising candidate gene
is suppressor of cytokine signaling 3 (SOCS3). A recent GWAS discovered a genomewide
significant association of IL15 with smoking behavior in males (50). As IL15 is an important
cytokine that regulates T and natural killer cell activation and proliferation, the genetic
association of IL15 with smoking may serve as paradigmatic for a novel mechanism for nicotine
dependence involving immune modulation through the IL15 pathway. Hence, it is reasonable
to suspect that variants in SOCS3 gene might influence the regulation of immune system
through a cytokine signaling pathway.
One advantage of GSMA is to confirm consistent evidence for linkage across studies. We
compared the regions nominated in the current GSMA with regions that were previously
identified as consistent across several independent genome scans. Genomic regions on
chromosomes 9 (from 91.9 to 136.5 cM based on the Marshfield map), 10 (62–158 cM), 11
(2–76 cM), and 17 (20–82 cM) have been replicated independently more often than other
regions (1). However, no strong evidence was achieved for these regions in the current GSMA.
GSMA is not used for exclusion mapping and the failure to show strong evidence of linkage
for these regions does not necessarily mean that those regions do not harbor risk loci for
smoking behavior. The GSMA method is particularly useful to identify regions that show weak
but consistent evidence of linkage across multiple studies. It does not take into account directly
whether the linkage signals aggregated have reached genomewide, or “suggestive,” evidence
for linkage, themselves. Nonetheless, it is notable that some evidence from the current GSMA
does support linkage on chromosome 11 and 17. For example, in the primary 30 cM GSMA
of smoking behavior, bin 11.1 (0–29.6 cM) showed nominal significance (PSR= 0.017).
Suggestive evidence for linkage has been achieved for bin 17.4 (95–126 cM) which is near the
region (20–82 cM) most frequently reported on chromosome 17.
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tAlthough GWAS has greater power to detect small effects on phenotype of common variants
and copy number variations (CNVs), an adequately powered linkage study design has the
advantage of detecting diverse genetic effects that segregate in families, including common
variants, multiple rare variants within one locus, and heritable CNVs. With the growing
evidence for the role of rare variants and CNVs in psychiatry disorders (60,61), the consensus
regions discovered by linkage studies may serve as a useful complement to the emerging
GWAS approach in reconstructing the genetic architecture of psychiatry disorders, especially
in pinpointing the causal rare variants that cannot be captured by common tag SNPs in the
GWAS design. In conclusion, the current meta-analysis including 15 genome scans of smoking
behavior has identified many regions showing evidence of linkage with smoking behavior.
Known and novel candidate genes map to the highly ranked regions are of particular interest.
Therefore, the regions identified in the current study deserve close attention and will be helpful
for candidate gene identification or target resequencing studies in the future.
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The primary 30 cM width GSMA results for all independent genome scans on smoking
behavior (3404 families with 10,253 genotyped subjects). Significance levels corresponding
to nominal (PSR < 0.05), suggestive (PSR < 0.0085) and genome-wide significance (PSR <
0.00042) are shown by horizontal lines.
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tFigure 2.
The primary 30 cM width GSMA results for all independent genome scans on FTND (1347
families with 3995 genotyped subjects). Significance levels corresponding to nominal (PSR <
0.05), suggestive (PSR < 0.0085) and genome-wide significance (PSR < 0.00042) are shown
by horizontal lines.
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tFigure 3.
The primary 30 cM width GSMA results for all independent genome scans on MaxCigs24 (966
families with 3273 genotyped subjects). Significance levels corresponding to nominal (PSR <
0.05), suggestive (PSR < 0.0085) and genome-wide significance (PSR < 0.00042) are shown
by horizontal lines.
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